Imprimis Pharmaceuticals (IMMY) Receives New Coverage from Analysts at B. Riley

B. Riley assumed coverage on shares of Imprimis Pharmaceuticals (NASDAQ:IMMY) in a research note issued to investors on Thursday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $11.50 price objective on the specialty pharmaceutical company’s stock.

Separately, Lake Street Capital assumed coverage on Imprimis Pharmaceuticals in a report on Monday, December 10th. They issued a buy rating and a $10.00 target price for the company.

Imprimis Pharmaceuticals stock opened at $5.83 on Thursday. Imprimis Pharmaceuticals has a 12 month low of $1.45 and a 12 month high of $6.50. The company has a quick ratio of 0.88, a current ratio of 1.13 and a debt-to-equity ratio of 2.84.

Imprimis Pharmaceuticals (NASDAQ:IMMY) last posted its earnings results on Tuesday, November 13th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.03). The business had revenue of $10.74 million during the quarter. Imprimis Pharmaceuticals had a negative return on equity of 231.16% and a negative net margin of 16.81%. Sell-side analysts predict that Imprimis Pharmaceuticals will post 0.69 EPS for the current fiscal year.

In related news, Director Robert J. Kammer sold 10,000 shares of Imprimis Pharmaceuticals stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $4.21, for a total value of $42,100.00. Following the completion of the sale, the director now owns 899,827 shares of the company’s stock, valued at $3,788,271.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 30,000 shares of company stock valued at $118,500 in the last ninety days. 13.78% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of IMMY. Opaleye Management Inc. bought a new stake in shares of Imprimis Pharmaceuticals in the third quarter worth $4,503,000. Renaissance Technologies LLC bought a new stake in shares of Imprimis Pharmaceuticals in the third quarter worth $259,000. Granite Investment Partners LLC grew its holdings in shares of Imprimis Pharmaceuticals by 44.5% in the third quarter. Granite Investment Partners LLC now owns 247,117 shares of the specialty pharmaceutical company’s stock worth $687,000 after acquiring an additional 76,155 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Imprimis Pharmaceuticals by 104.3% in the third quarter. JPMorgan Chase & Co. now owns 117,990 shares of the specialty pharmaceutical company’s stock worth $328,000 after acquiring an additional 60,248 shares during the period. Finally, Ardsley Advisory Partners grew its holdings in shares of Imprimis Pharmaceuticals by 42.9% in the second quarter. Ardsley Advisory Partners now owns 100,000 shares of the specialty pharmaceutical company’s stock worth $220,000 after acquiring an additional 30,000 shares during the period. 16.11% of the stock is owned by institutional investors.

Imprimis Pharmaceuticals Company Profile

Imprimis Pharmaceuticals, Inc, an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications.

Featured Article: Technical Analysis of Stocks and What It Means

Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply